However, given that CDK4/6 inhibitors combined with endocrine treatment improved both progression-free survival and overall survival and had a good toxicity profile, CDK4/6 inhibitors are considered the preferred option in ER+ gBRCA breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.